# Efficacy of Long-acting Octreotide (Sandostatin LAR) in Reducing Portal Pressure in Patients With Cirrhosis

> **NCT01188733** · PHASE1,PHASE2 · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 39 (actual)

## Conditions studied

- Cirrhosis
- Portal Hypertension
- Esophageal Varices

## Interventions

- **DRUG:** Long acting octreotide 10mg
- **DRUG:** Long acting Octreotide 30mg
- **DRUG:** Saline

## Key facts

- **NCT ID:** NCT01188733
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1998-06
- **Primary completion:** 2000-07
- **Final completion:** 2000-12
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2010-08-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01188733

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01188733, "Efficacy of Long-acting Octreotide (Sandostatin LAR) in Reducing Portal Pressure in Patients With Cirrhosis". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01188733. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*